Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 25;44(2):115274.
doi: 10.1016/j.celrep.2025.115274. Epub 2025 Feb 6.

Wnt signaling inhibits casein kinase 1α activity by modulating its interaction with protein phosphatase 2A

Affiliations
Free article

Wnt signaling inhibits casein kinase 1α activity by modulating its interaction with protein phosphatase 2A

Chen Shen et al. Cell Rep. .
Free article

Abstract

The mechanism by which Wnt signaling, an essential pathway controlling development and disease, stabilizes β-catenin has been a subject of debate over the last four decades. Casein kinase 1α (CK1α) functions as a pivotal negative regulator of this signaling pathway, initiating the events that destabilize β-catenin. However, whether and how CK1α activity is regulated in Wnt-off and Wnt-on states remains poorly understood. We now show that CK1α activity requires its association with the α catalytic subunit of protein phosphatase 2A (PPP2CA) on AXIN, the scaffold protein of the β-catenin destruction complex. Wnt stimulation induces the dissociation of PPP2CA from CK1α, resulting in CK1α autophosphorylation and its consequent inactivation. Moreover, autophosphorylated CK1α is enriched in a subset of colorectal cancers (CRCs) harboring constitutive Wnt activation. Our findings identify a mechanism by which Wnt stimulation inactivates CK1α, filling a critical gap in our understanding of Wnt signaling, with relevance for CRC.

Keywords: CK1α; CP: Cancer; CP: Molecular biology; Wnt signaling; autophosphorylation; colorectal cancer; protein phosphatase 2A.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests D.J.R. and E.L. are founders of StemSynergy Therapeutics, Inc., a company commercializing small-molecule signaling inhibitors, including Wnt inhibitors.

LinkOut - more resources